📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-23 19:46
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Transgene Biotek Statutory Auditor M/s Vasavi & Co. Resigns Citing Pre-occupation
Transgene Biotek announced that its Statutory Auditors, M/s Vasavi & Co., Chartered Accountants (FRN: 020965S), have resigned with immediate effect via letter dated September 22, 2026. The auditor cited pre-occupation with other assignments and inability to devote sufficient time as the sole reason for resignation. The micro-cap company, currently reporting negative net worth of ₹-9 crore and TTM losses of ₹-2 crore, stated it will initiate steps to appoint a successor under the Companies Act, 2013.
Confidence: HIGH
What changedM/s Vasavi & Co. has stepped down as the Statutory Auditor of Transgene Biotek effective September 22, 2026.
Why it mattersMid-term or sudden auditor resignations are a key corporate governance monitor, particularly for financially stressed companies with negative net worth and minimal revenues.
Resignation effective date: 22nd September, 2026Auditor FRN: 020965SCompany Market Cap: Rs 21 CrCompany Net Worth: Rs -9 Cr
📅 Short termLikely to create negative sentiment due to corporate governance optics surrounding sudden auditor departures.
📈 Long termStructural recovery hinges on finding credible auditors, resolving debt of ₹17 crore, and turning around operations from near-zero revenue.
⚠ Risk flags
- Governance concern regarding sudden auditor resignation
- Negative company net worth of ₹-9 Cr and debt of ₹17 Cr
- Near-zero revenue generation (TTM ₹0 Cr)
Key Highlights
Statutory Auditor M/s Vasavi & Co. resigned with immediate effect via letter dated 22nd September, 2026
Firm Registration Number (FRN) stated as 020965S
Auditor stated reason as pre-occupation in other assignments with no other material reasons disclosed
Company reported negative net worth of ₹-9 Cr and debt of ₹17 Cr in context
👀 What to Watch
Track the appointment of the incoming statutory auditor and verify disclosures in the upcoming quarterly filings for any qualification or audit adjustments.
Transgene Biotek Q1 Net Loss at ₹38.9 Lakhs; Revenue Remains Minimal at ₹6 Lakhs
Transgene Biotek reported a marginal revenue of ₹6.00 Lakhs for the quarter ended June 30, 2026, compared to ₹4.95 Lakhs in the year-ago period. The company continues to be loss-making, posting a net loss of ₹38.90 Lakhs, though slightly narrowed from ₹43.37 Lakhs YoY. Finance costs of ₹28.95 Lakhs remain the largest expense head, consuming nearly five times the quarterly revenue. The company is also managing multiple legal proceedings across NCLT, SAT, and the Enforcement Directorate.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results showing continued operational stagnation and provided updates on several ongoing legal disputes and the appointment of a new internal auditor.
Why it mattersWith a TTM revenue of nearly zero and a high debt-to-equity ratio of 2.05, the company's ability to service its ₹17 Cr debt and manage legal liabilities is a critical concern for solvency.
Revenue (Q1 FY27): ₹6.00 LakhsNet Loss (Q1 FY27): ₹38.90 LakhsFinance Costs: ₹28.95 LakhsDebt-to-Equity Ratio: 2.05Nitin Didwania Claim: ₹92.99 Lakhs
📅 Short termThe stock is likely to remain volatile and under pressure given the persistent losses and the overhang of multiple legal proceedings scheduled for August and September.
📈 Long termLimited; the company lacks a scalable revenue model and is burdened by high finance costs and legal liabilities that exceed its annual income.
⚠ Risk flags
- High debt-to-equity ratio (2.05)
- Persistent operational losses
- Multiple ongoing legal/regulatory disputes (ED, NCLT, SAT)
- Extremely low revenue base
Key Highlights
Revenue from operations for Q1 FY27 stood at ₹6.00 Lakhs.
Net loss for the quarter was ₹38.90 Lakhs, compared to a loss of ₹43.37 Lakhs in Q1 FY26.
Finance costs of ₹28.95 Lakhs accounted for 64.5% of total quarterly expenses.
Legal order in the Nitin Didwania matter requires payment of ₹92.99 Lakhs plus 6% interest; company has filed an appeal.
NCLT hearing adjourned to September 23, 2026, and ED hearing to September 10, 2026.
👀 What to Watch
Investors should closely monitor the outcomes of the NCLT and ED hearings in September 2026, as any adverse rulings could significantly impact the company's fragile ₹8 Cr net worth.
Transgene Biotek Q1 Net Loss of ₹38.9 Lakhs; ₹92.99 Lakh Legal Liability Under Appeal
Transgene Biotek reported a marginal revenue of ₹6.00 lakhs for Q1 FY27, compared to ₹4.95 lakhs in the same quarter last year. The company remains loss-making with a net loss of ₹38.90 lakhs, largely due to finance costs of ₹28.95 lakhs which consume nearly five times the quarterly revenue. Multiple legal proceedings involving the NCLT, SAT, and Enforcement Directorate have been adjourned to August and September 2026. Crucially, the company is appealing a court order to pay ₹92.99 lakhs plus 6% interest in a loan-related dispute, a significant amount relative to its ₹8 crore net worth.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and provided updates on six ongoing legal and regulatory matters.
Why it mattersWith TTM revenue near zero and a debt-to-equity ratio of 2.05, the company's survival is heavily dependent on the outcome of its various litigations and its ability to manage a ₹17 crore debt pile.
Q1 Revenue: ₹6.00 LakhsQ1 Net Loss: ₹38.90 LakhsFinance Costs: ₹28.95 LakhsLegal Liability (Didwania Case): ₹92.99 LakhsLiability vs Net Worth: ~11.6%
📅 Short termThe stock may remain volatile as the market digests the ongoing legal adjournments and the specific liability order of ₹92.99 lakhs.
📈 Long termThe company faces structural challenges including lack of operational scale and significant legal/regulatory overhangs that persist across multiple years.
⚠ Risk flags
- High debt-to-equity ratio (2.05)
- Negligible operational revenue
- Multiple ongoing litigations (NCLT, ED, SAT)
- Significant legal liability relative to net worth
Key Highlights
Revenue from operations for Q1 FY27 stood at ₹6.00 lakhs.
Net loss for the quarter was ₹38.90 lakhs, compared to a loss of ₹43.37 lakhs YoY.
Finance costs of ₹28.95 lakhs represent approximately 64% of total quarterly expenses.
Ordered to pay ₹92.99 lakhs plus 6% interest in the Nitin Didwania case; currently under appeal at Bombay High Court.
NCLT hearing adjourned to September 23, 2026, and SAT hearing to August 17, 2026.
👀 What to Watch
Investors should closely monitor the SAT hearing on August 17 and the ED Appellate Tribunal on September 10. The company's extremely low revenue base and high debt-servicing requirements make legal liabilities a critical risk factor.
